The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurologic Disorder Nervous System Diseases

Age range

0 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients under 18 years of age suffering from epilepsy
Patients who are taking Paraampanel

Exclusion criteria

Patients who are not in the above age groups and who are not using parampanel

Treatment and study plan

perampanel

Drug

Efficacy of epilepsy drugs

Primary outcomes

The efficacy of perampanel in young children with drug-resistant epilepsy

Time frame: 17 years

Because the current clinical research data on the use of Fycompa (perampanel) in children for the treatment of epilepsy is still insufficient, the purpose of this research is to review the efficacy of this drug in the treatment of children with epilepsy in our hospital in the past, so as to facilitate the future clinical treatment of children with epilepsy. Children have the possibility of therapeutic reference.

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

Director of Child Neurology, Department of Pediatrics, National Taiwan University Hospital

Important dates

Study start: 2018
Primary completion: 2020
Study completion: 2020
First posted: Oct 29, 2020
Registry last updated: Oct 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed